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Abstract
Background: The identification of four Consensus Molecular Subtypes (CMS1–4) of colorectal cancer forms a new
paradigm for the design and evaluation of subtype-directed therapeutic strategies. The most aggressive subtype -
CMS4 - has the highest chance of disease recurrence. Novel adjuvant therapies for patients with CMS4 tumours are
therefore urgently needed. CMS4 tumours are characterized by expression of mesenchymal and stem-like genes.
Previous pre-clinical work has shown that targeting Platelet-Derived Growth Factor Receptors (PDGFRs) and the related
KIT receptor with imatinib is potentially effective against mesenchymal-type colon cancer. In the present study we aim
to provide proof for the concept that imatinib can reduce the aggressive phenotype of primary CMS4 colon cancer.
Methods: Tumour biopsies from patients with newly diagnosed stage I-III colon cancer will be analysed with a novel
RT-qPCR test to pre-select patients with CMS4 tumours. Selected patients (n = 27) will receive treatment with imatinib
(400 mg per day) starting two weeks prior to planned tumour resection. To assess treatment-induced changes in the
aggressive CMS4 phenotype, RNA sequencing will be performed on pre- and post-treatment tissue samples.
Discussion: The development of effective adjuvant therapy for primary colon cancer is hindered by multiple factors.
First, new drugs that may have value in the prevention of (early) distant recurrence are almost always first tested in
patients with heavily pre-treated metastatic disease. Second, measuring on-target drug effects and biological
consequences in tumour tissue is not commonly a part of the study design. Third, due to the lack of patient selection
tools, clinical trials in the adjuvant setting require large patient populations. Finally, the evaluation of recurrence-
prevention requires a long-term follow-up. In the ImPACCT trial these issues are addressed by including newly
diagnosed pre-selected patients with CMS4 tumours prior to primary tumour resection, rather than non-selected
patients with late-stage disease. By making use of the pre-operative window period, the biological effect of imatinib
treatment on CMS4 tumours can be rapidly assessed. Delivering proof-of-concept for drug action in early stage disease
should form the basis for the design of future trials with subtype-targeted therapies in colon cancer patients.
Trial registration: ClinicalTrials.gov: NCT02685046. Registration date: February 9, 2016.
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Background
Mortality from colon cancer is almost invariably due to
the development of distant metastases. In current prac-
tice, pathological (TNM stage) and clinical characteris-
tics (age, co-morbidity) mainly determine the choice of
adjuvant chemotherapy. However, these features have
limited value in predicting which patients are at risk of
developing metastases. In clinical trials, the five-year
recurrence rate in stage III colon cancer patients is ap-
proximately 50% without adjuvant chemotherapy. With
adjuvant treatment this is reduced to ~35%, implying
that such treatment is only effective in a subgroup of
patients [1]. Consequently, the majority of patients are
currently being under- or over-treated. It is therefore
important to be able to identify patients who are at high
risk of recurrence and to develop more effective therap-
ies to prevent relapse. Relapse-prevention trials in the
adjuvant setting are challenging however, due to the long
follow-up periods and the large numbers of patients that
are required for sufficient statistical power. Prior evi-
dence of drug activity and the availability of a compan-
ion diagnostic tool for patient selection could greatly
facilitate the design and increase the quality of such
studies.
Novel adjuvant therapies should be based on an un-
derstanding of the pathways that drive metastasis for-
mation. Recent studies on molecular classification of
colon cancer have provided insight into these pathways.
Several research groups have independently developed
classification systems for primary colon cancer based
on gene expression profiles [2–8]. Cross-cohort analysis
of the results has led to the identification of four con-
sensus molecular subtypes (CMS1–4). Of these, CMS4
(~25% of colon cancers) is associated with a signifi-
cantly worse disease-free and overall survival [9]. Novel
treatment strategies for this subtype are thus particu-
larly needed.
The pro-metastatic pathways that are upregulated in
CMS4 provide opportunities for subtype-targeted ther-
apy. CMS4 tumours are characterised by high expres-
sion of stem cell and mesenchymal genes, and a high
stromal content [9]. We have previously shown that
Platelet-Derived Growth Factor Receptors (PDGFRs)
and KIT are highly expressed in mesenchymal-type
colon tumours and that their expression strongly corre-
lates with disease-free survival. Moreover, in vitro and
in vivo inhibition of PDGFR and KIT tyrosine kinase
signalling reduced invasiveness, metastatic potential and
stem-like characteristics of mesenchymal-type colon can-
cer [10–12]. Based on these findings we hypothesise that
patients with poor-prognosis mesenchymal-type colon
cancers could benefit from treatment with imatinib, a
tyrosine kinase inhibitor with high selectivity for
PDGFR and KIT.
To test this hypothesis in a proof-of-concept study, we
designed the ImPACCT trial (Imatinib as Pre-operative
Anti-Colon Cancer Targeted therapy). In ImPACCT,
patients with CMS4 colon cancer are identified with a
recently developed 4-gene RT-qPCR test that measures
PDGFRA, PDGFRB, PDGFC and KIT expression levels
in diagnostic tumour biopsies [13]. Pre-selected patients
with CMS4 tumours are then treated with imatinib dur-
ing the pre-operative window period (the time between
initial cancer diagnosis and surgery). This allows com-
parison of pre-treatment diagnostic tumour biopsies
with biopsies obtained from the resection specimen after
treatment. The primary objective is to assess whether
imatinib treatment reduces the aggressive phenotype
of CMS4 tumours in colon cancer patients. ImPACCT
may not only form the basis for future adjuvant
studies with imatinib, but could also serve as a blue-
print for other proof-of-concept studies with subtype-
targeted therapies.
Methods
Study design
The ImPACCT trial is an open-label, multi-centre
proof-of-concept study. The primary endpoint of this
trial is the effect of imatinib treatment on tumour biol-
ogy, which is a pharmacodynamic endpoint, and as such
this trial could be deemed a phase II/translational trial.
A study flow chart is depicted in Fig. 1.
Objectives
The primary objective of this trial is to investigate the
effects of treatment on pro-metastatic pathways in ag-
gressive primary CMS4 tumours. RNA sequencing will
be performed on pre- and post-treatment tissue samples
to document imatinib-induced genome-wide gene ex-
pression changes.
Secondary objectives include: to assess the extent of
inhibition of PDGFR- and KIT after imatinib treatment;
to relate intra-tumoural imatinib pharmacokinetics (PK)
to systemic imatinib concentrations; to relate the level of
inhibition of PDGFR/KIT signalling and the extent of
changes in gene expression to the systemic and intra-
tumoural PK of imatinib and its active metabolite
CGP74588; to assess changes in tumour markers during
treatment by measuring the concentrations of plasma-
CEA and circulating tumour DNA (ctDNA) and to study
the effects of imatinib on organoid-forming potential.
Finally, the effect of short-term exposure to imatinib im-
mediately followed by bowel surgery on the complica-
tion rate will be monitored.
Study population
All patients who are scheduled for a diagnostic colonos-
copy on account of clinical suspicion of colon carcinoma
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will be approached for permission to obtain extra biop-
sies for this study in case a tumour is found in the colon.
These biopsies are pre-screened with the new RT-qPCR
test that predicts the chance of a tumour being CMS4,
based on the combined expression of imatinib targets
PDGFRA, PDGFRB, PDGFC and KIT [13]. If the pre-
dicted chance of CMS4 in the biopsies is 50% or higher,
patients will be approached for imatinib therapy. The
study population that undergoes treatment with imatinib
will thus consist of treatment-naïve newly diagnosed
colon cancer patients with a tumour with a high prob-
ability of having the CMS4 phenotype. In- and exclusion
criteria for enrolment in the second part of the trial
(imatinib therapy) are listed in Table 1.
Study procedures
Patients pre-selected with the RT-qPCR test will be
screened by a medical oncologist for inclusion in the
second part of this study. Included patients will receive
treatment with imatinib starting two weeks prior to
planned tumour resection. Imatinib will be administered
orally at a daily dosage of 400 mg for two weeks, with
the last dose given within 12 h before surgery. Patients
are requested to register drug intake and any adverse
events in a patient diary. Before the start of imatinib
therapy and at the end of the treatment period, blood
samples will be obtained to measure ctDNA and
plasma-CEA. Plasma imatinib trough levels will be
determined on the day of surgery. Immediately following
tumour resection, biopsies will be taken from the surgi-
cal specimen (post-treatment biopsies). Gene and pro-
tein expression of the pre-treatment biopsies (from
colonoscopy) and post-treatments biopsies will be
compared to assess the effects of imatinib therapy on
PDGFR- and KIT-signalling and on the mesenchymal
gene expression profile. After surgery, patients will be
Fig. 1 Study flow chart
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monitored according to standard of care. Any postopera-
tive adverse events up until 14 days after discontinuation
of study medication (end of study) will be documented.
Sample size calculation
This study is designed as a proof-of-concept study with
multiple outcomes of interest. We expect the effect size
of imatinib treatment on the various parameters to be
very high, since we specifically select patients who ex-
press high levels of the drug targets. However, we are
aware of possible factors that may reduce the observed
effect size. This includes intra-tumour heterogeneity in
target expression – causing potential misclassification –
and variation in drug distribution throughout the
tumour and between patients. Therefore, we anticipate a
medium to high Cohen effect size for the primary end-
point (i.e. Cohen’s effect size of 0.65). To demonstrate
such an effect, we need to include 27 (evaluable) pa-
tients, based on a two-sided paired-samples t-test with a
significance level α of 0.05 and power 1-β of 90%. We
specifically chose this high power in order not to dismiss
effects that are potentially relevant for further develop-
ment of imatinib therapy in colorectal cancer patients.
Given that approximately 25% of colon cancers are
CMS4, at least 4*27 = 108 eligible patients with newly
diagnosed colon cancer will need to be pre-screened
with the RT-qPCR test. Since <10% of the patients
undergoing colonoscopy are diagnosed with colon can-
cer, at least 1.100 patients will have to be approached for
pre-screening informed consent.
Statistical analyses
Imatinib-induced changes in the expression of specific
gene signatures associated with CMS4 will be assessed
by RNA-sequencing analysis. The signatures will be ob-
tained from published literature and our own data. In
addition, imatinib-induced gene expression changes will
be analysed in a non-biased way by gene ontology and
gene enrichment analyses. Using the appropriate statistical
tests depending on distribution of the data (paired sam-
ples t-test in case of normal distribution or Wilcoxon
signed-rank test if the distribution remains non-normal
even after transformation) we will test whether there is a
significant change in gene signature expression. Phosphor-
ylation of PDGFRα/β and KIT will be quantitatively
assessed as a fraction of the total amount of PDGFRα/β
and KIT present in a sample. Post-treatment imatinib-
induced inhibition of PDGFR phosphorylation will be
compared relative to the pre-treatment sample (i.e. the pa-
tient’s internal control) using the appropriate statistical
tests. Correlations between plasma trough levels and
intratumoural concentration of imatinib, and between the
extent of PDGFR and KIT inhibition and systemic/intratu-
moural imatinib concentrations will be evaluated using
Pearson correlation coefficient. The Wilcoxon matched
pairs signed rank test will be used to compare serial
ctDNA and CEA levels. Organoid-forming potential of
the tumours after imatinib therapy will be compared with
the general success rate of organoid-establishment from
colon cancers, using a Fisher exact test. In case of missing
data, samples will be excluded pair-wise.
Discussion
Targeted anti-cancer therapies that seem promising in
pre-clinical and early-phase clinical trials often fail to
show benefit in phase III randomized controlled trials.
Up to 60 % of phase III trials have negative outcomes
[14, 15]. This high failure rate underscores the need for
optimization of trial design, including better patient se-
lection. Since the successful addition of oxaliplatin to
the adjuvant chemotherapy regimen in 2004 [16], no
further advances have been made in the outcome of pa-
tients with stage II/III colon cancer. The lack of recent
positive adjuvant chemotherapy trials is partly due to the
Table 1 In- and exclusion criteria for treatment with imatinib
Inclusion criteria Exclusion criteria
- Male or female aged ≥18 years;
- Histologically proven adenocarcinoma of the colon;
- Completed cancer staging with CT-abdomen and CT-thorax/X-thorax
according to hospital’s standard of care;
- Confirmed eligibility for surgery with curative intent as deemed by the
hospital’s multidisciplinary board review;
- Test positive for CMS4 subtype;
- ≥4 properly stored pre-treatment biopsies for gene expression analysis/
ELISA;
- WHO performance status 0 or 1;
- Adequate haematology status and organ function (defined as: normal
creatinine clearance (≥60 ml/min (MDRD)), ALAT within 2.5× upper limit
of normal (ULN), PT-INR < 1.5, leukocytes >1,5*10^9/L, Hb > 6.0 mmol/
L, platelets >100*10^9/L);
- Willingness and ability to comply with scheduled visits, treatment plans
and laboratory tests;
- Provision of written informed consent.
- The presence of synchronous distant metastases;
- Current hospital standard of care dictates that subject should undergo
any neoadjuvant therapy;
- Concurrent participation in another clinical trial using any medicinal
product, or participation in such a trial in the period of three months
prior to the current trial;
- Women who are pregnant, plan to become pregnant or are lactating
during the study or for up to 30 days after the last dose of imatinib;
- Known HIV or Hepatitis B/C infection;
- Known symptomatic congestive heart failure;
- Co-morbidity requiring concomitant treatment with drugs that act as
strong inducers of CYP3A4 or with drugs with a narrow therapeutic
range influenced by imatinib.
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fact that hardly any new drugs are actually tested in the
adjuvant setting. Novel treatments are generally first tested
in patients with metastatic disease who have no regular
treatment options left, and who have often received mul-
tiple lines of systemic treatment. Therapies aimed at pre-
venting the development or outgrowth of metastases are
probably most effective at early disease stages, but their
clinical development may be terminated due to lack of effi-
cacy in late-stage disease [17]. Moreover, new (combin-
ation) treatments that are effective in metastatic disease do
not necessarily have value in the adjuvant setting, as exem-
plified by trials PETACC-03 (5-FU/LV plus irinotecan)
[18], NSABP C-08 (FOLFOX6 plus bevacizumab) [19] and
N0147 (FOLFIRI plus cetuximab) [20]. To address this
problem, design and approval of clinical trials in which
promising drugs are tested in treatment-naïve patients
with early-stage disease, rather than in late-stage patients
who progressed under standard treatment, is needed.
Prospective stratification and/or inclusion based on
predictive molecular biomarkers will presumably im-
prove trial results by enrichment for responsive patients
[21]. However, microsatellite instability is currently the
only molecular marker that is being used in the clinical
decision process for adjuvant chemotherapy in colon
cancer [22]. The four recently identified CMSs in colon
cancer show marked differences in the activity of various
biological pathways, which could provide the basis for
subtype-specific targeted therapy [9]. CMS4 (the mesen-
chymal/stem-like/stroma-rich subtype) has the poorest
prognosis and, importantly, this subtype seems associated
with a lack of benefit from oxaliplatin treatment [23].
These findings call for clinical trials with novel therapies
specifically targeting CMS4 tumours. In ImPACCT we
aim to deliver proof-of-concept that PDGFR/KIT inhib-
ition with imatinib reduces the aggressive phenotype of
newly diagnosed primary CMS4 colon tumours. Deliver-
ing proof-of-concept for drug activity in early stages of
drug development is pivotal to prevent unfounded trial
phase transition [14, 15].
ImPACCT is conducted with treatment-naïve patients
during the pre-operative window period, which allows us
to obtain high quality tissue material before and after
imatinib therapy without additional interventions: pre-
treatment samples will be obtained during diagnostic
colonoscopy and post-treatment biopsies are collected
from the resection specimen; both procedures are part
of standard of care. By comparison of pre- and post-
treatment tissue samples, the effects of imatinib on
CMS4 tumours can be evaluated at a cellular level. The
treatment period of 14 days is within the normal time
frame from diagnosis to surgery (the pre-operative win-
dow). We expect that two weeks of treatment will be
sufficient to induce changes in gene expression: given
that steady state plasma concentrations will be attained
within four days (the plasma half-life of imatinib is 18 h
[24]), patients will be exposed to the full dose for ten
days. The chosen daily dose of 400 mg is the standard
dose for chronic myeloid leukaemia, gastrointestinal
stromal tumours (GIST) and myelodysplastic syndrome.
Experimental therapy during the pre-operative window
period could potentially lead to an increase in postoper-
ative complications. However, based on two phase II
trials that evaluated the use of neoadjuvant imatinib
therapy for otherwise irresectable or metastatic GIST,
we believe it is safe to administer the last dose of ima-
tinib within 12 h before surgery. In these trials imatinib
was administered for several months and stopped one
day prior to surgery. Both studies concluded that this
approach was feasible, and the reported postoperative
complications were acceptable and not out of the ordin-
ary considering the extensive abdominal surgery [25, 26].
Instead of assessing a clinical endpoint (e.g. disease-
free survival), this proof-of-concept trial investigates a
surrogate endpoint (gene expression changes) to demon-
strate a ‘biological’ treatment effect. This endpoint
requires a relatively limited sample size and can be de-
termined after only two weeks of therapy, which limits
the burden placed on participants. If treatment effects
are indeed demonstrated, knowledge of the size of the
effect on tumour biology can be used to drive the design
of a larger randomised phase II trial.
The design of the ImPACCT trial presented here allows
rapid evaluation of the mechanism of action of a targeted
therapy in a subtype-stratified patient population by ana-
lysis of paired pre- and post-treatment biopsies, without
interfering with or delaying standard-of-care, by making
use of the pre-operative window period. This design
can serve as a blueprint for subtype-directed proof-
of-concept trials in colon cancer, with the ultimate
goal of designing effective adjuvant therapy that eradi-
cates occult metastases.
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